Overview Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids Status: Terminated Trial end date: 2009-08-01 Target enrollment: Participant gender: Summary The safety of Proellex 25 and 50 mg administered once daily for three treatment cycles (four months each) will be evaluated. Phase: Phase 3 Details Lead Sponsor: Repros Therapeutics Inc.